Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Inclusion Criteria

• •Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma. Patients with pancreatic acinar cell carcinoma may also be included.
• •Is previously untreated for metastatic pancreatic ductal adenocarcinoma, was diagnosed within the past 3 months, and is expected to receive standard treatment with gemcitabine and nab-paclitaxel.
• •Measurable disease on CT or MRI scan by RECIST v 1.1 criteria.
• •ECOG Performance Status 0 or 1.
• •Adult, age ≥ 18 years, male or female.
• •Females of child-bearing potential must have a negative serum pregnancy test within 14 days prior to start of study treatment and must use an adequate method of contraception during the study. All sexually active males must also use an adequate method of contraception during the study. Female subjects will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months of consecutive amenorrhea, without other known or suspected cause) and over 55 years old or have been sterilized surgically (i.e., bilateral tubal ligation, hysterectomy or bilateral oophorectomy, all with surgery at least one month before dosing).
• •Adequate bone marrow, hepatic, renal and coagulation function as defined by the following:
• •1. Absolute neutrophil count ≥1.5 x 109/L
• •2. Hemoglobin ≥9.0 g/dL (90 g/L)
• •3. Platelets ≥100 x 109/L
• •4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN) (if no hepatic metastases). If hepatic tumor involvement, AST and ALT ≤5 x ULN.
• •5. Bilirubin ≤1.5 x ULN
• •6. Prothrombin time (PT) / international normalized ratio (INR) ≤1.5 x ULN if not on anti-coagulants
• •7. Calculated creatinine clearance \>50 mL/min using the Cockcroft and Gault equation
• •QTc interval ≤ 470 msec at Baseline.
• •Life expectancy ≥ 3 months.
• •Willing and able to provide written informed consent: voluntary agreement to participate in the study following disclosure of risks and procedures required, including possibility of onset of exocrine pancreatic insufficiency with subsequent requirement for life-long pancreatic enzyme replacement.